Faeth Therapeutics, Inc.
FTH- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001829802
In the last 90 days, Faeth Therapeutics, Inc. insiders filed 1 open-market purchase and 0 sales; 45 institutions reported holding it in 13F filings for Q2 2026, worth $333.8M in total; no superinvestor holds it.
13F holders, Q1 2025
Institutional positions in Faeth Therapeutics, Inc. as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 20
- −4 vs. Q4 2024
- Shares held
- 1.93M
- −434.7K (−18.4%) vs. Q4 2024
- Total value
- $760.2K
- −$397.7K (−34.3%) vs. Q4 2024
- New holders
- 2
- 5 more added
- Sold out
- 6
- 5 more reduced
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting FTH on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 45 | $333.8M |
| Q1 2026 | 30 | $68.0M |
| Q4 2025 | 10 | $514.8K |
| Q3 2025 | 9 | $466.2K |
| Q2 2025 | 10 | $600.0K |
| Q1 2025 | 20 | $760.2K |
| Q4 2024 | 24 | $1.16M |
| Q3 2024 | 19 | $1.32M |
| Q2 2024 | 24 | $1.31M |
| Q1 2024 | 25 | $2.43M |
| Q4 2023 | 24 | $2.05M |
| Q3 2023 | 23 | $2.38M |
| Q2 2023 | 26 | $3.58M |
| Q1 2023 | 27 | $4.71M |
| Q4 2022 | 28 | $3.93M |
| Q3 2022 | 31 | $4.47M |
| Q2 2022 | 40 | $7.06M |
| Q1 2022 | 43 | $8.21M |
| Q4 2021 | 38 | $19.7M |
| Q3 2021 | 42 | $37.1M |
| Q2 2021 | 34 | $22.7M |
| Q1 2021 | 40 | $45.8M |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding Faeth Therapeutics, Inc.; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 585,576 | $230.7K | 0.00% | −8,878−1.5% | Reduced |
| Ikarian Capital, LLC | 449,963 | $177.3K | 0.06% | −200,000−30.8% | Reduced |
| Catalio Capital Management, LP | 294,374 | $116.0K | 0.03% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 177,300 | $69.9K | 0.00% | +20,500+13.1% | Added |
| Geode Capital Management, LLC | 150,709 | $59.4K | 0.00% | +1,822+1.2% | Added |
| Boothbay Fund Management, LLC | 108,658 | $42.8K | 0.00% | −64,140−37.1% | Reduced |
| UBS Group AG | 42,541 | $16.8K | 0.00% | +42,539+2,126,950.0% | Added |
| Northern Trust Corp | 25,983 | $10.2K | 0.00% | 00.0% | Unchanged |
| State Street Corp | 25,774 | $10.2K | 0.00% | 00.0% | Unchanged |
| Cresset Asset Management, LLC | 19,671 | $7.75K | 0.00% | 00.0% | Unchanged |
| NWF Advisory Services Inc. | 16,514 | $6.51K | 0.00% | 00.0% | Unchanged |
| Raymond James Financial Inc | 14,000 | $5.52K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 9,219 | $3.63K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 5,404 | $2.13K | 0.00% | −44−0.8% | Reduced |
| Barclays PLC | 2,558 | $1.01K | 0.00% | +2,558 | New |
| JPMorgan Chase & Co | 702 | $276 | 0.00% | −3−0.4% | Reduced |
| BNP Paribas Arbitrage, SA | 160 | $63 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 142 | $56 | 0.00% | +6+4.4% | Added |
| Citigroup Inc | 124 | $49 | 0.00% | +124 | New |
| SBI Securities Co., Ltd. | 92 | $36 | 0.00% | +21+29.6% | Added |
| XTX Topco Ltd | 0 | $0 | 0.00% | −62,903−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −57,717−100.0% | Sold out |
| Bridgeway Capital Management, LLC | 0 | $0 | 0.00% | −47,900−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −38,051−100.0% | Sold out |
| Deuterium Capital Management, LLC | 0 | $0 | 0.00% | −11,000−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −11,600−100.0% | Sold out |